Over 1,000 Chemotherapy Protocols And Counting

Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/d

20 May

Melanoma

New Indication: Adjuvant Pembrolizumab for Melanoma

Double-blind, randomised, phase 3 study (KEYNOTE-716) Newly diagnosed, completely resected stage IIB or IIC melanoma Pembrolizumab (n=483) or placebo (n=486)

20 May

Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Double-blind, randomized, placebo-controlled, phase 3 trial Newly diagnosed IDH1-mutated acute myeloid leukemia Ineligible for intensive induction chemotherapy Oral ivosidenib and

20 May

Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Open-label, randomised, phase 3 study (PEACE-1) De novo metastatic prostate adenocarcinoma Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/

20 May

Prostate Cancer

New Indication: Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and doce

20 May

Cervical Cancer

New Reference: Cemiplimab for Cervical Cancer

Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1) Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy Cemiplimab (n=304) or sin

16 Mar

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2-Mutant NSCLC

Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight

20 May

GastroEsophageal Cancer

New Indication: Nivolumab in Esophageal SCC

Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy f

26 Nov

Hodgkin Lymphoma

New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma

Multicenter, randomized, open-label trial Stage 3 or 4 advanced Hodgkin’s lymphoma A+AVD (n:664) or ABVD (n:670)

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries